Steinberg Marshall, Silverstein Irwin
International Pharmaceutical Excipient Council, Arlington, Virginia, USA.
Int J Toxicol. 2003 Sep-Oct;22(5):373-5. doi: 10.1177/109158180302200506.
The laws governing the U.S. Food and Drug Administration (FDA) do not provide for the approval of stand-alone excipients. Current regulations do not permit the use of excipients, but allow their use. The acceptance process for excipients is slow and only recently did the FDA propose draft guidance for nonclinical studies for pharmaceutical excipients. The FDA has made four suggestions to the U.S. Pharmacopoeia concerning including excipient monographs in the National Formulary for excipients not yet allowed. This article reviews these four proposals to identify the proposal that is most appropriate.
美国食品药品监督管理局(FDA)的相关法律并未规定对单一辅料进行批准。现行法规不允许使用辅料,但又允许其使用。辅料的审批过程缓慢,直到最近FDA才提出了关于药用辅料非临床研究的指导草案。FDA已就将尚未获批的辅料专论纳入《国家处方集》一事向美国药典提出了四条建议。本文对这四条建议进行了审查,以确定最合适的建议。